Kura Oncology (KURA) Corporate presentation summary

Strategic vision and growth priorities

• Focused on precision oncology with a commercial-stage portfolio and deep pipeline targeting cancer treatment gaps.

• 2026 priorities include executing the KOMZIFTI launch, expanding clinical data, and advancing darlifarnib and next-gen menin inhibitors.

• Vision for 2030+ includes establishing KOMZIFTI as standard of care in menin-driven AML and expanding into additional solid tumor indications.

• Strategic collaboration with Kyowa Kirin enables broad development and commercialization while retaining key U.S. rights.

Product pipeline and clinical development

• KOMZIFTI (ziftomenib) approved for R/R NPM1-m AML; comprehensive development strategy targets up to 50% of AML patients, a ~$7B U.S. market.

• Multiple ongoing trials for ziftomenib in various AML subtypes and combinations, including frontline and relapsed/refractory settings.

• Darlifarnib (FTI) in combination with cabozantinib shows encouraging activity in RCC, with expansion into other solid tumors and combinations planned.

• Next-generation menin inhibitors advancing for diabetes, cardiometabolic, and solid tumor indications.

Financial highlights and commercial performance

• $5.8M in KOMZIFTI net product revenue in 1Q 2026, first full quarter of launch.

• $580.8M in cash and equivalents as of March 31, 2026, expected to fund key programs through pivotal trial topline results in 2028.

• Strong payer positioning and rapid adoption with 85 new patient starts and 157 total prescriptions in the first quarter.